ArticleCancer research communications2025

Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas.

Niccolò G Santin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.